Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
393
Recruiting Now
393
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07627698 Phase 1, Phase 2
Recruiting
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Condition
Unresectable Melanoma
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
NCT07672301 Phase 1, Phase 2
Recruiting
Total Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilate...
Condition
Total Knee Arthroplasty (TKA)
Enrollment
150 pts
Location
United States
Sponsor
University of Chicago
NCT06598371 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engine...
Condition
Select Advanced Solid Tumors
Enrollment
141 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04176198 Phase 1, Phase 2
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Condition
Myelofibrosis
Enrollment
240 pts
Location
United States, Australia, Belgium
Sponsor
Sumitomo Pharma America, Inc.
NCT04959175 Phase 1, Phase 2
Recruiting
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Olde...
Condition
Hematologic Neoplasms
Enrollment
320 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT06718192 Phase 1, Phase 2
Recruiting
A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cry...
Condition
Verruca Plantaris
Enrollment
70 pts
Location
China
Sponsor
The Fourth Affiliated Hospital
NCT06129734 Phase 1, Phase 2
Recruiting
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allo...
Condition
Myeloid Malignancy
Enrollment
20 pts
Location
United States
Sponsor
Benjamin Tomlinson
NCT06325709 Phase 1, Phase 2
Recruiting
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-...
Condition
Chronic Granulomatous Disease (CGD)
Enrollment
15 pts
Location
United States
Sponsor
National Institute of Allergy
NCT04146298 Phase 1, Phase 2
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic ...
Condition
Pancreatic Cancer
Enrollment
30 pts
Location
China
Sponsor
Changhai Hospital
NCT06757855 Phase 1, Phase 2
Recruiting
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromo...
Condition
CML,Blast Phase
Enrollment
29 pts
Location
China
Sponsor
Institute of Hematology & Bloo
NCT07761533 Phase 1, Phase 2
Recruiting
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Condition
Acute Myeloid Leukemia (AML)
Enrollment
29 pts
Location
China
Sponsor
Chaser Therapeutics, Inc.
NCT07805252 Phase 1, Phase 2
Recruiting
Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity ...
Condition
Advanced Solid Tumors Cancer
Enrollment
195 pts
Location
Spain
Sponsor
Orion Corporation, Orion Pharm
NCT05654649 Phase 1, Phase 2
Recruiting
Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Se...
Condition
Postoperative Ileus
Enrollment
90 pts
Location
Egypt
Sponsor
Assiut University
NCT07513038 Phase 1, Phase 2
Recruiting
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
Condition
Biliary Atresia
Enrollment
20 pts
Location
United States
Sponsor
Boston Children's Hospital
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Condition
HER2-positive Breast Cancer
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo
NCT06106685 Phase 1, Phase 2
Recruiting
Washed Microbiota Transplantation for Chronic Constipation in Adults
Condition
Constipation
Enrollment
18 pts
Location
China
Sponsor
The Second Hospital of Nanjing
NCT04165590 Phase 1, Phase 2
Recruiting
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
Condition
Advanced Malignant Solid Tumor
Enrollment
60 pts
Location
China
Sponsor
CAS Lamvac Biotech Co., Ltd.
NCT02259556 Phase 1, Phase 2
Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refra...
Condition
Hodgkin's Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07070323 Phase 1, Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody...
Condition
T-Cell Acute Lymphocytic Leukemia
Enrollment
54 pts
Location
China
Sponsor
Beijing GoBroad Hospital
NCT07002203 Phase 1, Phase 2
Recruiting
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Condition
Solid Tumors
Enrollment
10 pts
Location
Thailand
Sponsor
Seqker Biosciences, Inc.
NCT07185841 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macu...
Condition
Wet Age-related Macular Degeneration (AMD)
Enrollment
198 pts
Location
China
Sponsor
Fujian Haixi Pharmaceuticals C
NCT05801237 Phase 1, Phase 2
Recruiting
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Condition
Locally Advanced/Metastatic Solid Tumors
Enrollment
120 pts
Location
China
Sponsor
Shanghai HyaMab Biotech Co.,Lt
NCT06134375 Phase 1, Phase 2
Recruiting
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Condition
Triple Negative Breast Cancer
Enrollment
204 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT07146672 Phase 1, Phase 2
Recruiting
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radi...
Condition
Solid Tumor Cancer
Enrollment
12 pts
Location
China
Sponsor
Shanghai Cell Therapy Group Co
NCT05256641 Phase 1, Phase 2
Recruiting
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lympho...
Condition
Diffuse Large B-Cell Lymphoma
Enrollment
24 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology